ArticleInternational journal of nanomedicine2025
Development and Optimization of Oral Dissolution Films for Enhanced Delivery of Ebastine-Loaded Solid Lipid Nanoparticles.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Approximately 10-30% of the worldwide population suffers from allergic diseases. Although ebastine (EBT) is described as a potential treatment for allergies, its effects are compromised due to poor solubility and low bioavailability. Methods: This study introduced a novel delivery platform for ebastine by combining solid lipid nanoparticles (SLNs) with oral dissolution films (ODFs). Ebastine SLNs were fabricated using hot melt and ultrasonic emulsification methods, and the SLNs' formulation was optimized by a central composite rotatable design. The developed SLNs were further introduced into a mixed polymer solution of PVA and HPMC to prepare ODFs using the solvent casting method. Results: The optimized EBT-SLNs with spherical structures demonstrated nanoparticle size (147.5 ± 3.32 nm), low polydispersity index (PDI, 0.106 ± 0.005), high entrapment efficiency (86.7%), as well as drug loading (10.02%), respectively. The optimum formulation of ODFs was composed of equal proportion of HPMC and PVA according to normalization methods by evaluation of physicochemical properties including physical appearance, folding endurance and disintegration time. Scanning electron microscopy results disclosed that EBT-SLNs were confined within the network of ODFs and no aggregation SLNs was found. Reconstitution experiments showed EBT-SLNs were still within the nanometers range and maintained a homogenous state, suggesting that incorporation of SLNs into ODFs not compromised their nanoparticulate properties. The in vitro drug release patterns from ODFs containing EBT-SLNs exhibited a fast release profile compared to the commercial EBT tablets. Discussion: The developed system demonstrates enhanced solubility, stability, and bioavailability of ebastine, offering a promising alternative to traditional oral tablets, with potential advantages in patient compliance and rapid drug onset. Therefore, the ODFs containing SLNs can be considered as an efficient approach for EBT administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.